LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:

OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]openaire.eu

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Singleton, Rosalyn J.; Bruden, Dana; Brooks, Lisa; DeLeon, Jenni; Vercelline, Anna; Butler, Jay C. (2012)
Publisher: Co-Action Publishing
Journal: International Journal of Circumpolar Health
Languages: English
Types: Article
Subjects: respiratory syncytial virus, palivizumab, Alaska Native

Classified by OpenAIRE into

mesheuropmc: education, health care economics and organizations, geographic locations
International Journal of Circumpolar Health 65:1 2006Keywords: respiratory syncytial virus, palivizumab, Alaska Native
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Leader S, Kohlhase K. Respiratory syncytial viruscoded pediatric hospitalizations 1997 to 1999. Pediatr Infect Dis J 2002;21:629-32.
    • 2. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 1998;102:531-7.
    • 3. Karron RA, Singleton R, Bulkow L, et al. Severe respiratory syncytial virus disease in Alaska Native children. J Infect Dis 1999;180:41-9.
    • 4. Singleton R, Dooley L, Bruden D, Raelson S, Butler JC. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J 2003;22(6):540-5.
    • 5. AAP Committe on Infectious Disease and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IVIG. Pediatrics 1998;102:1211-18.
    • 6. Mullins JA, LaMonte AC, Bresee JS, Anderson LJ. Substantial variability in RSV seasonality in the U.S. Pediatr Infect Dis J 2003;22:857-62.
    • 7. Golombek SG, Berning F, Lagamma EF. Compliance with prophylaxis for respriatory syncytial virus infection in a home setting. Pediatr Infect Dis J 2004;23:318-22.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Collected from

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok